Article
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib.
Blood cells, molecules & diseases - 15 Feb 2012
Vivona Douglas, Bueno Carolina T, Lima Luciene T, Hirata Rosario D C, Hirata Mario H, Luchessi André D, Zanichelli Maria A, Chiattone Carlos S, Guerra-Shinohara Elvira M
Abstract excerpt
BACKGROUND: Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor used for treating chronic myeloid leukemia (CML). IM has high efficacy, however some individuals develop a resistance due to impaired bioavailability. Polymorphisms in genes encoding membrane transporters such as ABCB1 have been associated with differences in protein expression and function that influence the response to several drugs....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.